CN102014873A - 糖玻璃化的病毒样颗粒 - Google Patents

糖玻璃化的病毒样颗粒 Download PDF

Info

Publication number
CN102014873A
CN102014873A CN2009801146099A CN200980114609A CN102014873A CN 102014873 A CN102014873 A CN 102014873A CN 2009801146099 A CN2009801146099 A CN 2009801146099A CN 200980114609 A CN200980114609 A CN 200980114609A CN 102014873 A CN102014873 A CN 102014873A
Authority
CN
China
Prior art keywords
compositions
vlp
powder
sugared
glass
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2009801146099A
Other languages
English (en)
Chinese (zh)
Inventor
丹尼什·谢诺伊
詹姆斯·鲁宾逊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novavax Inc
Original Assignee
Novavax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novavax Inc filed Critical Novavax Inc
Publication of CN102014873A publication Critical patent/CN102014873A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16023—Virus like particles [VLP]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2009801146099A 2008-02-25 2009-02-25 糖玻璃化的病毒样颗粒 Pending CN102014873A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3124308P 2008-02-25 2008-02-25
US61/031,243 2008-02-25
PCT/US2009/035122 WO2009108689A1 (en) 2008-02-25 2009-02-25 Sugar glassified virus like particles (vlps)

Publications (1)

Publication Number Publication Date
CN102014873A true CN102014873A (zh) 2011-04-13

Family

ID=41016454

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2009801146099A Pending CN102014873A (zh) 2008-02-25 2009-02-25 糖玻璃化的病毒样颗粒

Country Status (8)

Country Link
EP (1) EP2254554A1 (https=)
JP (1) JP2011514337A (https=)
CN (1) CN102014873A (https=)
BR (1) BRPI0908861A2 (https=)
CA (1) CA2716546A1 (https=)
MX (1) MX2010009351A (https=)
RU (1) RU2010139478A (https=)
WO (1) WO2009108689A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103929979A (zh) * 2011-10-11 2014-07-16 Mjn美国控股有限责任公司 包含麦芽三糖的组合物，和使用该组合物抑制脱水过程所造成的损伤的方法
CN104080476A (zh) * 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗
CN108472357A (zh) * 2015-09-04 2018-08-31 创赏有限公司 Vlp稳定的疫苗组合物
CN115350281A (zh) * 2022-09-20 2022-11-18 华派生物工程集团有限公司 一种病毒样颗粒疫苗冻干保护剂及其制备方法

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11446374B2 (en) 2008-12-09 2022-09-20 Novavax, Inc. Modified RSV F proteins and methods of their use
JP5813513B2 (ja) 2008-12-09 2015-11-17 ノババックス，インコーポレイテッド 修飾ｒｓｖｆタンパク質及びその使用方法
EP2519539A4 (en) * 2009-12-28 2013-11-13 Ligocyte Pharmaceuticals Inc METHODS FOR STABILIZING VIRUS-LIKE PARTICULATE SOLUTIONS BASED ON INFLUENZA-INFLUENZA-VIRUSED VIRUSES
GB201002419D0 (en) * 2010-02-12 2010-03-31 Isis Innovation Stable live vaccine formulations
MX349294B (es) * 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2011336413B2 (en) 2010-12-02 2015-01-22 Oncolytics Biotech Inc. Liquid viral formulations
US20140127260A1 (en) * 2011-06-24 2014-05-08 Ramesh V. Chintala Hpv vaccine formulations comprising aluminum adjuvant and methods of producing same
RU2720808C2 (ru) 2013-09-03 2020-05-13 Джорджия Тек Рисёч Корпорейшн Термостабильные препараты вакцин и микроиглы
AU2014364930B2 (en) 2013-12-16 2017-06-15 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
MX2016007786A (es) 2013-12-16 2017-03-03 Massachusetts Inst Technology Formulaciones de sal de micronutrientes fortificadas.
IL310015B2 (en) * 2013-12-31 2026-02-01 Access To Advanced Health Inst Single vial formulation
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
EP3139952A1 (en) * 2014-05-06 2017-03-15 The Regents of the University of Colorado, a body corporate Compositions, methods and uses for thermally stable human papillomavirus formulations
EP4494650A3 (en) 2015-09-03 2025-03-26 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
WO2019023196A1 (en) 2017-07-24 2019-01-31 Novavax, Inc. METHODS AND COMPOSITIONS FOR TREATING RESPIRATORY DISEASE
EP3768308A4 (en) 2018-03-19 2022-01-26 Novavax, Inc. MULTIVALENT INFLUENZA NANOPARTICLE VACCINES
EP3976092A1 (en) * 2019-05-25 2022-04-06 Infectious Disease Research Institute Composition and method for spray drying an adjuvant vaccine emulsion
JP7776145B2 (ja) 2020-05-13 2025-11-26 マサチューセッツ インスティテュート オブ テクノロジー ポリマーマイクロデバイスの組成物およびがん免疫療法におけるその使用
WO2025058011A1 (ja) * 2023-09-13 2025-03-20 国立大学法人大阪大学 経鼻投与用組成物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6290991B1 (en) * 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
CN1777411B (zh) * 2003-02-24 2013-01-02 药品生产公司 经粘膜药物递送系统
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US7871632B2 (en) * 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GB0502661D0 (en) * 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TW200640492A (en) * 2005-02-21 2006-12-01 Lg Life Sciences Ltd Sustained release composition of protein drug

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080476A (zh) * 2011-09-30 2014-10-01 诺瓦瓦克斯股份有限公司 用于呼吸道合胞病毒的重组纳米颗粒rsv f疫苗
CN103929979A (zh) * 2011-10-11 2014-07-16 Mjn美国控股有限责任公司 包含麦芽三糖的组合物，和使用该组合物抑制脱水过程所造成的损伤的方法
CN108472357A (zh) * 2015-09-04 2018-08-31 创赏有限公司 Vlp稳定的疫苗组合物
CN115350281A (zh) * 2022-09-20 2022-11-18 华派生物工程集团有限公司 一种病毒样颗粒疫苗冻干保护剂及其制备方法
CN115350281B (zh) * 2022-09-20 2026-01-02 华派生物技术(集团)股份有限公司 一种病毒样颗粒疫苗冻干保护剂及其制备方法

Also Published As

Publication number Publication date
EP2254554A1 (en) 2010-12-01
WO2009108689A1 (en) 2009-09-03
JP2011514337A (ja) 2011-05-06
MX2010009351A (es) 2011-03-04
RU2010139478A (ru) 2012-05-20
CA2716546A1 (en) 2009-09-03
BRPI0908861A2 (pt) 2018-02-06

Similar Documents

Publication Publication Date Title
CN102014873A (zh) 糖玻璃化的病毒样颗粒
JP6817370B2 (ja) 弱毒生ウイルス組成物
KR102136036B1 (ko) 비강내 전달을 위한 방법 및 조성물
EP1150918B1 (en) Method of manufacturing therapeutic calcium phosphate particles
EP2709657B1 (en) Thermostable vaccine compositions and methods of preparing same
AU2002366267B2 (en) Pharmaceutical compositions in particulate form
EP2368576B1 (en) Functionally reconstituted viral membranes containing adjuvant
JP2001524533A (ja) 粒子状ワクチン組成物の経皮的送達
US20020068090A1 (en) Calcium phosphate particles as mucosal adjuvants
CN1674867A (zh) 抗原组合物
AU2019389772A1 (en) Oral dispersible vaccine comprising virosomes
US20110150927A1 (en) Stabilisation of Viral Microparticles
Amorij et al. Development of stable influenza vaccine powder formulations for non-parenteral dosage forms: challenges and possibilities.
EP1471034A2 (en) Therapeutic calcium phosphate particles and methods of manufacture and use
HK40049705A (en) Oral dispersible vaccine comprising virosomes
Hassett Ultra stable glassy state vaccines containing adjuvants
HK1070045A (en) Therapeutic calcium phosphate particles and methods of manufacture and use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20110413